Compositions of non-ionic block copolymers to treat autoimmune and inflammatory diseases, and to reduce graft/implantation, and methods of use thereof

A composition for reducing inflammation, auto-immune response, and rejection of graft/implantation consisting essentially of non-ionic block copolymer F127 and non-ionic block copolymer L61 of the formula

• wherein F127 has a molecular weight of 12600, an average number of oxypropylene units (n) of 65.2, an average number of oxyethylene units (m) of 200.4, and a hydrophilic-lipophilic balance of 22;
• L61 has a molecular weight of 2000, an average number of oxypropylene units (n) of 31.0, an average number of oxyethylene units (m) of 4.5, and a hydrophilic-lipophilic balance of 3;
• and
• wherein the amount of the non-ionic block copolymer F127 is at least twice the amount of the non-ionic block copolymer L61.

A method for reducing inflammation comprising the step of administering a composition comprising at least one non-ionic block copolymer of the formula

• selected from the group consisting of F127 and L61 wherein,
• F127 has a molecular weight of 12600, an average number of oxypropylene units (n) of 65.2, an average number of oxyethylene units (m) of 200.4, and a hydrophilic-lipophilic balance of 22;
• and
• L61 has a molecular weight of 2000, an average number of oxypropylene units (n) of 31.0, an average number of oxyethylene units (m) of 4.5, and a hydrophilic-lipophilic balance of 3.

A method for reducing auto-immune response in an animal comprising the step of administering a composition comprising at least one non-ionic block copolymer of the formula

• selected from the group consisting of F127 and L61 wherein,
• F127 has a molecular weight of 12600, an average number of oxypropylene units (n) of 65.2, an average number of oxyethylene units (m) of 200.4, and a hydrophilic-lipophilic balance of 22;
• and
• L61 has a molecular weight of 2000, an average number of oxypropylene units (n) of 31.0, an average number of oxyethylene units (in) of 4.5, and a hydrophilic-lipophilic balance of 3.

A method for treating an animal having rheumatoid arthritis, an inflammatory disease, or an auto-immune disease comprising the step of administering to the in a composition comprising at least one non-ionic block copolymer of the formula

• selected from the group consisting of F127 and L61 wherein,
• F127 has a molecular weight of 12600, an average number of oxypropylene units (n) of 65.2, an average number of oxyethylene units (m) of 200.4, and a hydrophilic-lipophilic balance of 22;
• and
• L61 has a molecular weight of 2000, an average number of oxypropylene units (n) of 31.0, an average number of oxyethylene units (m) of 4.5, and a hydrophilic-lipophilic balance of 3.